Zanubrutinib Versus Ibrutinib in Relapsed/Refractory Chronic Lymphocytic Leukemia and Small Lymphocytic Lymphoma: Interim Analysis of a Randomized Phase III Trial

Peter Hillmen, Wojciech Jurczak, Meng Ji et al.|Journal of Clinical Oncology|2022

Cited by 93